Efficacy and safety of degludec U100 versus glargine U300 for the early postoperative management of patients with type 2 diabetes mellitus undergoing coronary artery bypass graft surgery: A non‐inferiority randomized trial
Authors' conclusion
Treatment with degludec U100 is as effective and safe as glargine U300 for the early postoperative hospital management of patients with T2D undergoing CABG.
Study context
- Population
- Patients with T2D undergoing coronary artery bypass graft (CABG) surgery, early postoperative periodrandomized 1:1
- Participants
- 239 patients
- Comparison
- Degludec U100 vs glargine U300 as basal in a basal-bolus regimen with glulisine before meals
- Degludec U100n = 122
- Glargine U300n = 117reference
- Primary endpoint
- Mean differences between groups in daily BG concentrations
Methodological detailsnon-inferiority
- Non-inferiority
Primary result
As reported in the abstract
Mean daily BG concentration · early postoperative period
- No differences in mean daily BG concentrations between treatment groups
Further findings
Mean % of readings within target BG 70-180 mg/dl
- No differences between treatment groups
Daily basal insulin dose
- No differences between treatment groups
LOS
- No differences between treatment groups
Safety
Hospital complications
- No differences between treatment groups
Hypoglycemia: BG <70 mg/dl
- No differences in proportion of patients between degludec-100 and glargine-300
Hypoglycemia: BG <54 mg/dl
- No differences in proportion of patients between degludec-100 and glargine-300
Original publication
Efficacy and safety of degludec U100 versus glargine U300 for the early postoperative management of patients with type 2 diabetes mellitus undergoing coronary artery bypass graft surgery: A non‐inferiority randomized trial. Diabet Med. Published 16 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →